NewzIn June, Chinese regulators granted approval for the world’s first CAR-T cell therapy specifically designed to treat solid tumour cancers. Developed by a Shanghai-based pharmaceutical company, the treatment represents a significant milestone in oncology research within the region.
Following this regulatory authorization, a New Zealander diagnosed with advanced stomach and small intestine cancer received the therapy at a Shanghai hospital in July. This patient marks the first international individual to undergo the procedure, highlighting the global reach and clinical application of this new medical development.
In-depth summary · AI, neutral